Panjon Ltd
Incorporated in 1983, Panjon Ltd manufactures and trades in consumers and pharmaceutical
products[1]
- Market Cap ₹ 33.5 Cr.
- Current Price ₹ 19.5
- High / Low ₹ 30.0 / 16.1
- Stock P/E 46.5
- Book Value ₹ 9.93
- Dividend Yield 0.00 %
- ROCE 4.97 %
- ROE 4.29 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Company's working capital requirements have reduced from 133 days to 77.0 days
Cons
- Company has a low return on equity of 2.72% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.47 | 12.26 | 13.98 | 20.10 | 25.94 | 26.43 | 14.49 | 8.41 | 6.09 | 12.55 | 30.46 | 47.62 | |
| 22.54 | 12.35 | 14.00 | 19.68 | 25.63 | 26.11 | 14.30 | 12.45 | 6.09 | 12.57 | 29.83 | 46.62 | |
| Operating Profit | -3.07 | -0.09 | -0.02 | 0.42 | 0.31 | 0.32 | 0.19 | -4.04 | 0.00 | -0.02 | 0.63 | 1.00 |
| OPM % | -15.77% | -0.73% | -0.14% | 2.09% | 1.20% | 1.21% | 1.31% | -48.04% | 0.00% | -0.16% | 2.07% | 2.10% |
| -1.51 | 0.43 | 0.52 | 0.21 | 0.36 | 0.29 | 0.33 | 0.30 | 0.38 | 0.45 | 0.31 | 0.30 | |
| Interest | 0.00 | 0.17 | 0.19 | 0.28 | 0.24 | 0.15 | 0.10 | 0.07 | 0.05 | 0.06 | 0.18 | 0.27 |
| Depreciation | 0.13 | 0.14 | 0.13 | 0.11 | 0.15 | 0.27 | 0.23 | 0.20 | 0.21 | 0.22 | 0.23 | 0.30 |
| Profit before tax | -4.71 | 0.03 | 0.18 | 0.24 | 0.28 | 0.19 | 0.19 | -4.01 | 0.12 | 0.15 | 0.53 | 0.73 |
| Tax % | -27.18% | -1,133.33% | 33.33% | 50.00% | 53.57% | 115.79% | 47.37% | 3.49% | -575.00% | 0.00% | 24.53% | 0.00% |
| -3.43 | 0.36 | 0.12 | 0.12 | 0.14 | -0.03 | 0.10 | -4.15 | 0.81 | 0.15 | 0.40 | 0.72 | |
| EPS in Rs | -2.21 | 0.23 | 0.08 | 0.08 | 0.09 | -0.02 | 0.06 | -2.68 | 0.52 | 0.09 | 0.23 | 0.42 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 27% |
| 3 Years: | 98% |
| TTM: | 56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 48% |
| 3 Years: | -4% |
| TTM: | 80% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -3% |
| 3 Years: | 3% |
| Last Year: | 4% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 15.50 | 16.31 | 17.17 | 17.17 |
| Reserves | 0.52 | 0.89 | 1.00 | 1.13 | 1.27 | 1.23 | 1.31 | -2.84 | -2.02 | -1.46 | -0.62 | -0.13 |
| 1.52 | 1.41 | 1.26 | 1.89 | 1.84 | 1.56 | 1.33 | 0.81 | 0.78 | 1.44 | 2.65 | 4.01 | |
| 0.51 | 0.24 | 0.28 | 0.29 | 0.34 | 0.92 | 1.12 | 0.58 | 0.64 | 1.10 | 0.85 | 0.71 | |
| Total Liabilities | 18.05 | 18.04 | 18.04 | 18.81 | 18.95 | 19.21 | 19.26 | 14.05 | 14.90 | 17.39 | 20.05 | 21.76 |
| 0.92 | 0.84 | 0.74 | 0.72 | 0.87 | 1.12 | 0.96 | 0.95 | 0.91 | 0.90 | 1.09 | 1.44 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.08 | 1.08 | 1.08 | 1.09 | 1.09 | 1.08 | 1.07 | 1.07 | 1.08 | 1.08 | 1.10 | 1.11 |
| 16.05 | 16.12 | 16.22 | 17.00 | 16.99 | 17.01 | 17.23 | 12.03 | 12.91 | 15.41 | 17.86 | 19.21 | |
| Total Assets | 18.05 | 18.04 | 18.04 | 18.81 | 18.95 | 19.21 | 19.26 | 14.05 | 14.90 | 17.39 | 20.05 | 21.76 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.89 | -0.20 | 0.18 | -0.17 | 0.49 | 0.35 | 0.34 | 1.82 | 0.04 | -0.42 | -4.34 | -0.43 | |
| 4.74 | -0.06 | -0.04 | -0.08 | -0.31 | -0.51 | -0.06 | -0.19 | -0.19 | -0.21 | -0.44 | -0.66 | |
| -5.14 | -0.19 | -0.17 | 0.40 | -0.05 | -0.07 | -0.24 | -0.51 | 0.18 | 1.88 | 2.50 | 1.38 | |
| Net Cash Flow | 0.49 | -0.44 | -0.03 | 0.15 | 0.13 | -0.22 | 0.04 | 1.12 | 0.04 | 1.25 | -2.27 | 0.28 |
| Free Cash Flow | 5.54 | -0.26 | 0.14 | -0.25 | 0.18 | -0.17 | 0.27 | 1.63 | -0.14 | -0.62 | -4.76 | -1.08 |
| CFO/OP | -29% | 222% | -1,100% | -29% | 177% | 122% | 195% | -45% | 2,000% | -689% | -32% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 184.28 | 261.39 | 21.67 | 16.89 | 23.64 | 45.57 | 93.45 | 26.47 | 93.50 | 52.64 | 39.06 | 41.93 |
| Inventory Days | 46.16 | 101.43 | 95.13 | 66.63 | 57.65 | 59.10 | 120.11 | 306.47 | 610.67 | 152.35 | 65.87 | 47.05 |
| Days Payable | 7.20 | 4.14 | 2.93 | 2.19 | 3.98 | 11.48 | 28.24 | 19.51 | 63.17 | 6.93 | 3.56 | 2.75 |
| Cash Conversion Cycle | 223.24 | 358.68 | 113.87 | 81.33 | 77.31 | 93.20 | 185.32 | 313.43 | 641.00 | 198.07 | 101.37 | 86.22 |
| Working Capital Days | 262.83 | 428.41 | 177.80 | 123.85 | 112.85 | 138.51 | 261.22 | 277.76 | 480.07 | 216.38 | 105.45 | 77.03 |
| ROCE % | -14.51% | 1.13% | 2.08% | 2.87% | 2.80% | 1.84% | 1.59% | -24.93% | 1.23% | 1.37% | 4.00% | 4.97% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing Sales INR Hundreds |
|
||||||||||
| Trading Sales INR Hundreds |
|||||||||||
| Number of Permanent Employees Number |
|||||||||||
| Trade Receivables Turnover Ratio Percentage |
|||||||||||
| Geography-wise Revenue: Central INR Hundreds |
|||||||||||
| Geography-wise Revenue: West INR Hundreds |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 May - Enclosed Herewith Newspaper Announcement for the Board Meeting dated 29.05.2026 for Financial Results for Quarter and Year ended 31.03.2026
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Panjon’s FY26 secretarial compliance report notes overall compliance, except website documents not updated.
-
BM OUTCOME DATED 29.05.2026 FOR Appointment Of Internal Auditor M/S B. Jakhetiya & CO. Chartered Accountants For The Financial Year 2026-27
29 May - Approved audited FY26 results; appointed M/s. B. Jakhetiya & Co. as internal auditor.
-
FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2026
29 May - Board approved FY26 audited results on 29 May 2026 and appointed internal auditor B. Jakhetiya & Co.
-
Board Meeting Outcome for Board Meeting Outcome Dated 29/05/2026 For Financial Results For The Quarter And Year Ended - March 31 2026
29 May - Board approved audited FY26 results and appointed internal auditor; statutory auditor issued unmodified opinion.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
a) Panjon is in the business of specialized Medicinal, Digestive, Ayurvedic & Confectionary products
b) Presently, the company is mainly into reality development
c) The company, considering the slowdown in the reality sector and considering the experiences of the promoters, has started the trading business of Petroleum product. The turnover is mainly
from the trading activities of the petroleum products.
d) The company also started venturing into
the waste management activities of medical
bi-products.